Skip to main content

Advertisement

Log in

Cetuximab-dependent ADCC in cancer: dream or reality?

  • Letter to the editor
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hildebrandt B, le Coutre P, Nicolaou A et al (2007) Cetuximab: appraisal of a novel drug against colorectal cancer. Recent Results Cancer Res 176:135–143

    Article  CAS  PubMed  Google Scholar 

  2. Vincenzi B, Schiavon G, Silletta M et al (2008) The biological properties of cetuximab. Crit Rev Oncol Hematol 68:93–106

    Article  PubMed  Google Scholar 

  3. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–3454

    Article  CAS  PubMed  Google Scholar 

  4. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  CAS  PubMed  Google Scholar 

  5. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  CAS  PubMed  Google Scholar 

  6. Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129

    Article  CAS  PubMed  Google Scholar 

  7. López-Albaitero A, Lee CS, Morgan S et al (2009) Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853–1862

    Article  PubMed  Google Scholar 

  8. Kono K, Takahashi A, Ichihara F et al (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813–5817

    CAS  PubMed  Google Scholar 

  9. de Souza AP, Bonorino C (2009) Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9:1317–1332

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alessandro Ottaiano.

Additional information

Please note that we are simultaneously publishing a letter by Ottaiano et al., which is a response to the paper by López-Albaitero et al., published in 2009 (Cancer Immunol Immunother 58:1853–1862), and a response by Ferris and Ferrone to the Ottaiano letter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ottaiano, A., Scala, S. & Iaffaioli, V.R. Cetuximab-dependent ADCC in cancer: dream or reality?. Cancer Immunol Immunother 59, 1607–1608 (2010). https://doi.org/10.1007/s00262-010-0884-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-010-0884-3

Keywords

Navigation